100 μl in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 μg per ml BSA and 50% glycerol.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser294 conjugated to KLH
Protein G purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
PGR, 607311, P06401, PR, NR3C3, 5241, Progesterone Receptor (phospho S294), Progesterone Receptor (phospho Ser294), Progesterone Receptor (pS294), Progesterone Receptor (pSer294), Progesterone Receptor phospho S294, Progesterone Receptor phospho Ser294, Phospho Progesterone Receptor (S294), Phospho Progesterone Receptor (Ser294), Phospho Progesterone Receptor (pS294), Phospho Progesterone Receptor (pSer294)
Nucleoplasmic shuttling is both homone- and cell cycle-dependent. On hormone stimulation, retained in the cytoplasm in the G(1) and G(2)/M phases. Mainly nuclear.
The human Progesterone Receptor (PgR) is a member of the steroid family of nuclear receptors. PgR is found as a 120kDa protein (Form B) or a 94kDa protein (Form A) due to the use of alternative translation initiation sites. In its inactive state, PgR forms a multiprotein complex which includes heat shock proteins and immunophins. Upon binding of progesterone hormone to its receptor, there is a conformational change that allows dimerization and binding of the receptor to progesterone response elements (PRE) sequences, resulting in activated transcription. When bound to DNA, PgR can positively or negatively regulate gene transcription through the recruitment of coactivator (e.g. SRC-1) or corepressor (e.g. NCoR) proteins.